Annovis Bio (ANVS) News Today $4.89 +0.01 (+0.10%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Annovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Merit Financial Group LLCMerit Financial Group LLC lifted its stake in shares of Annovis Bio, Inc. (NYSE:ANVS - Free Report) by 269.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,516 shares of the company's stock after buying an additional 71,81January 24, 2025 | marketbeat.comAnnovis Bio Secures U.S. Patent for Neuroprotective Drug BuntanetapJanuary 17, 2025 | msn.comAnnovis Bio granted U.S. patent covering buntanetapJanuary 14, 2025 | markets.businessinsider.comAnnovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global ProtectionJanuary 14, 2025 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Buy" by AnalystsShares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buyJanuary 11, 2025 | marketbeat.comAnnovis Bio: Strategic Advancements and Phase 3 Trial Acceleration Justify Buy RatingJanuary 8, 2025 | markets.businessinsider.comFDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s StudyJanuary 8, 2025 | msn.comAnnovis Bio announces FDA acceptance of protocol for Phase 3 AD studyJanuary 8, 2025 | markets.businessinsider.comFDA genehmigt überarbeitetes Protokoll für Annovis Bios Phase-3-Studie zur Alzheimer-KrankheitJanuary 7, 2025 | de.investing.comFDA genehmigt überarbeitetes Studienprotokoll von Annovis Bio für Alzheimer-StudieJanuary 7, 2025 | de.investing.comAnnovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study ProtocolJanuary 7, 2025 | msn.comFDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development PathwayJanuary 7, 2025 | finance.yahoo.comAnnovis Bio (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’December 30, 2024 | theglobeandmail.comAnnovis Bio (NYSE: ANVS) Committed to Ensuring Highest Standards in Buntanetap TrialsDecember 23, 2024 | theglobeandmail.comAnnovis Bio-Aktie erreicht 52-Wochen-Tief bei 4,52 US-DollarDecember 19, 2024 | de.investing.comShort Interest in Annovis Bio, Inc. (NYSE:ANVS) Declines By 5.8%Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 1,310,000 shares, a decline of 5.8% from the November 15th total of 1,390,000 shares. Based on an average daily trading volume, of 254,500 shares, the days-to-cover ratio is presently 5.1 days.December 17, 2024 | marketbeat.comAnnovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Buy" from AnalystsAnnovis Bio, Inc. (NYSE:ANVS - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strongDecember 17, 2024 | marketbeat.comAnnovis Bio Advances Alzheimer’s and Parkinson’s Drug TrialsDecember 12, 2024 | markets.businessinsider.comAnnovis Bio Appoints William Fricker as Interim CFODecember 10, 2024 | markets.businessinsider.comAnnovis Bio ernennt Interims-CFODecember 9, 2024 | de.investing.comAnnovis Bio (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative DiseasesDecember 5, 2024 | theglobeandmail.comAnnovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s MarketplaceDecember 5, 2024 | finance.yahoo.comAnnovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's MarketplaceDecember 5, 2024 | globenewswire.com/C O R R E C T I O N -- Today's Marketplace/December 4, 2024 | prnewswire.comAnnovis Bio Announces Investor Webcast to Share Key UpdatesNovember 29, 2024 | msn.comAnnovis to Host Year-End Investor Webcast on December 11, 2024November 25, 2024 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of "Buy" from AnalystsShares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have earned a consensus recommendation of "Buy" from the seven research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and onNovember 22, 2024 | marketbeat.comStrategic Buy Rating on Annovis Bio Amid Regulatory Alignment and Growth Potential in Alzheimer’s MarketNovember 15, 2024 | markets.businessinsider.comQ4 Earnings Estimate for Annovis Bio Issued By HC WainwrightAnnovis Bio, Inc. (NYSE:ANVS - Free Report) - HC Wainwright dropped their Q4 2024 earnings estimates for shares of Annovis Bio in a report released on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.38) for the quarter, doNovember 14, 2024 | marketbeat.comAnnovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial UpdatesNovember 13, 2024 | msn.comAnnovis Bio (NYSE: ANVS) CEO to Showcase Buntanetap’s Dual Benefits at NIA WorkshopNovember 12, 2024 | theglobeandmail.comAnnovis sees cash runway for Phase 3 preparatory studies, entering AD studyNovember 12, 2024 | markets.businessinsider.comAnnovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)November 12, 2024 | markets.businessinsider.comBuy Rating for Annovis Bio Driven by Promising Regulatory Progress and Potential of BuntanetapNovember 12, 2024 | markets.businessinsider.comAnnovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial BackingNovember 11, 2024 | theglobeandmail.comAnnovis Bio Reports Third Quarter Financial Results and Provides Business UpdateNovember 11, 2024 | markets.businessinsider.comWill Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?November 11, 2024 | finance.yahoo.comAnnovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Annovis Bio in a research report on Monday.November 11, 2024 | marketbeat.comAnnovis Bio Welcomes New Senior Clinical Scientist to Lead Key StudiesNovember 9, 2024 | msn.comAnnovis Bio, Inc.: Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical ScientistNovember 7, 2024 | finanznachrichten.deAnnovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical ScientistNovember 7, 2024 | markets.businessinsider.comAnnovis Bio appoints Peterson as Senior Clinical ScientistNovember 7, 2024 | markets.businessinsider.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis BioOctober 31, 2024 | globenewswire.comAnnovis Bio (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to PatientsOctober 30, 2024 | theglobeandmail.comAnnovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by BrokeragesShares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have earned a consensus rating of "Buy" from the seven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one hasOctober 28, 2024 | marketbeat.comMaxim Group Upgrades Annovis Bio (ANVS)October 26, 2024 | msn.comAnnovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s StudiesOctober 25, 2024 | theglobeandmail.comAnnovis Bio upgraded to Buy at Maxim following buntanetap updateOctober 25, 2024 | markets.businessinsider.comAnnovis Bio (NYSE:ANVS) Upgraded at Maxim GroupMaxim Group raised shares of Annovis Bio from a "hold" rating to a "buy" rating and set a $25.00 price target on the stock in a report on Friday.October 25, 2024 | marketbeat.comAnnovis Bio to Present Key Alzheimer’s Research at CTAD ConferenceOctober 24, 2024 | msn.com Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address ANVS Media Mentions By Week ANVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANVS News Sentiment▼1.880.76▲Average Medical News Sentiment ANVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANVS Articles This Week▼14▲ANVS Articles Average Week Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Atea Pharmaceuticals News Today Rezolute News Today AC Immune News Today DiaMedica Therapeutics News Today C4 Therapeutics News Today Benitec Biopharma News Today COMPASS Pathways News Today Amylyx Pharmaceuticals News Today Canopy Growth News Today UroGen Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANVS) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
